Ventriculo-Peritoneal Shunt Infections in Infants and Children by Bokhary, MM Aly & Kamal, HM
www.ljm.org.ly    Original Article  
Libyan J Med, AOP: 080104
Ventriculo-Peritoneal Shunt Infections 
in Infants and Children 
 
Bokhary MM  Aly
1 and Kamal HM
2 
 
 
1 Department of Neurosurgery 
 2 Department of Pediatrics. King Fahad Hofuf Hospital, Hofuf, Saudi Arabia.  
 
Abstract 
Objective: To determine the rate and the type of ventriculoperitoneal (VP) shunt infections in infants and children admitted 
to King Fahad Hofuf hospital of Al-Ahsaa area at the Eastern Province of Saudi Arabia. Methods: From mid 2003 to end of 
2006; VP shunt infection episodes were reviewed. Once infection was suspected, a cerebrospinal fluid (CSF) sample was 
taken and empirical antibiotics were recommended. Once infection was confirmed, VP shunt was removed and external 
ventricular drainage (EVD) was inserted until CSF became sterile after which a new shunt was inserted. Results: 25.9% of 
patients with VP shunts had infections which represents 29.3% of the procedures. 40% of infected patients had recurrent 
episodes.  59.1% of infections occurred throughout the first two months following insertion. Single pathogen was isolated in 
each episode. Pseudomonas auerginosa represented 50% of isolated pathogens compared with 18.2% with Staphylococcus 
epidermidis. Conclusions: There is a high incidence of VP shunt infections in King Fahad Hofuf hospital when compared with 
other international centres. Gram negative organisms are the most common cause of the infection.
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Introduction 
Infection is a common complication of 
ventriculoperitoneal shunt (VP) placement [1]. It occurs in 
nearly 10% of patients [2,3,4]. Shunt infections generally 
occur within the first two months after surgery and 
Staphylococcus epidermidis is the most common cause 
[5]. When a shunt infection is suspected, percutaneous 
needle aspiration of the shunt reservoir is usually 
diagnostic [6]. The preferred treatment of CSF shunt 
infections involves intravenous antimicrobial therapy, 
surgical removal of the infected shunt, installation of an 
external ventricular drainage (EVD) device, and insertion 
of a new shunt once the CSF is sterile [5.[ 
 
The aim of this retrospective study is to determine the 
rate and the type of VP shunt infections in infants and 
children admitted to Neurosurgical and Paediatric 
Departments at King Fahad Hofuf Hospital (KFHH) of Al-
Ahsaa area in the Eastern Province of Saudi Arabia. This 
hospital is the only referral centre for pediatric 
neurosurgical cases in this area. 
 
Patients and methods 
Over a three-and-a-half year period from mid 2003 till 
the end of 2006, 58 infants and children with 
hydrocephalus (30 girls and 28 boys) were subjected to 75 
VP shunt procedures. VP shunt infection was suspected by 
two or more of the following clinical findings: fever, 
recurrent vomiting, poor feeding, depressed 
consciousness, irritability, seizures, and bulging tense 
anterior fontanel. Once infection was suspected, CSF 
(from shunt reservoir or from ventricular tapping), blood, 
and urine samples were taken in addition to other sepsis 
work up (full blood count, estimation sedimentation rate, 
C- reactive protein, full blood biochemistry, arterial blood 
gases, and chest x-ray.( 
 
Empirical antibiotics were then commenced pending 
culture and sensitivity results. Computerized tomography 
(CT) scanning of the brain was also considered. Once CSF 
infection had been confirmed, VP shunt was removed and 
EVD inserted until 3 CSF successive samples became 
sterile and its protein content got back to normal. A new 
shunt was then inserted. Ethical approval was gained 
before collection of patient data. 
Results
Fifteen patients (25.9%), 8 girls and 7 boys, had 22 
shunt infection episodes (29.3%). Table (1) shows ages of 
procedures and times of infections.  
 
Table 1  Ages of procedures and time of infections 
Age of  1st procedure 
Times of infection 
(after procedure) 
1d-1m  7  1st 2 m  13 
1m-6m 6  2m-1y  6 
>6m 2  >1y  3 
Total 15  Total  22 
 
Table 2  Original causes of hydrocephalus. Six patients (40%) had 
more than one episode of shunt infections within one month after 
shunt insertion.  
Original cause of hydrocephalus 
IVH 6  (40%) 
Isolated aquiduct stenosis  4 (26.7%) 
Postmeningitic 3  (20%) 
Aquiduct stenosis and spina bifida  2 (13.3%) 
Total 15  (100%) 
 
Table 3  A single pathogen was found in each episode of 
infection. Gram negative bacteria (GNB) represented the vast 
majority of pathogens (17 episodes, 77.3%) while S. epidermidis 
was isolated in only 4 episodes (18.2%). Concomitant blood and 
urine cultures showed no growth in all patients. 
Type of organism  No and % 
Pseudomonas Auerginosa  11 (50%) 
Enterococcus faecalis  4 (18.2%) 
Staphylococcus Epidermidis  4 (18.2%) 
Serratia Merescens  1 (4.5%) 
Haemophilus influenza  1 (4.5%) 
Candida Albicans  1 (4.5%) 
Total 22  (100%) 
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The usual empirical antibiotics used were Ceftazidime 
plus Cloxacillin or Vancomycin plus Ceftazidime. With 
established sensitivity, Ceftriaxone was used in 1 episode 
of infection (Haemophilus influenza), Piperacillin plus 
Gentamicin in 1 episode (Pseudomonas), Amphotericin B 
in 1 episode (Candida), Ceftazidime in 4 episodes 
(Pseudomonas), Meropenam in 6 episodes (4 with 
Enterococci, 1 with Serratia and one with Pseudomonas) 
and Vancomycin in 9 episodes (4 episodes with S. 
epidermidis and 5 episodes with Pseudomonas).  
 
The median duration of intravenous antibiotics 
treatment was 10 days after CSF being culture negative as 
well as clinical improvement (usually between 14 - 21 
days). The patient with candidal infection was given 
Amphotericin B therapy for a total of 25mg/kg for 30 
days; followed by oral fluconazole for one month.  
 
Intraventricular antibiotics with Gentamicin or 
Vancomycin for 5 days was tried in 7 episodes (3 with 
Serratia, 2 with Enterococcus faecalis and 2 patients with 
S. epidermidis). One episode of P. auerginosa ended with 
death from septic shock 5 days after commencing 
conventional plus intraventricular therapy. 
 
Two patients, one with candidal infection and another 
with Enterococcus infection, were treated with 
anticonvulsant medication (phenobarbitone). Beside the 
above mentioned; short term morbidity (3 months after 
recovery from infection) particularly neurological disability 
was not significantly different from age-and-sex matched 
patients with VP shunts and did not develop CSF 
infections. 
 
Discussion
It was suggested that the real incidence of infected 
shunts might be higher than what had previously been 
suspected in cases of malfunctioning shunts because 
shunts, when removed, frequently showed microbial 
growth [7]. In our study, infected removed shunt tubes (in 
case of malfunction) were not considered as clues for 
shunt infection. That if was not associated with positive 
CSF culture and clinical features suggestive of VP shunt 
infection; because of high possibility of contamination of 
these tubes. This is in agreement with opinions expressed 
in pervious studies [8]. 
 
The incidence of VP shunt infections in our study was 
relatively high (25.9%) compared to many other studies 
where the rate of infection varies from 3.2-17% [6,9-13]. 
GNB represented 81.3% of pathogens in our study 
compared to 7-20% in other studies [9,11,14]. In 
contrast, gram positive bacteria (all were S. epidermidis) 
were isolated in 12.5% in our study compared to 47-80% 
in other studies [9,10,11,13,14]. Patients with 
hydrocephalus secondary to IVH or meningitis were the 
most infected with GNB (8 patients, 13 infection episodes) 
or Candida (1 patient). This might be explained by 
impaired local resistance resulting from past infection or 
hemorrhage. Though GNB infections can be associated 
with poor prognosis, there was one case death in our 
study. Other patients did not show neurological damage 
after 6 months of the onset of infection. These results are 
compatible with a previous study by Stamos et al. [15] 
who concluded that patients with GNB CSF shunt 
infections often present relatively well clinically and they 
can be successfully treated. In this study, the high 
prevalence of GNB infections was not only noticed in 
patients with VP shunts, but also in the majority of cases 
with postoperative sepsis particularly related to intestinal 
and urologic diseases. Despite the strict anti-infectious 
protocols followed in all hospital areas particularly within 
the operating rooms and intensive care units, resistant 
strains of GNB particularly P. auerginosa and Klebsiella 
have been emerging. Empirical abuse of antibiotics, 
particularly second and third generation cephalosporins, 
within most of the medical centres in the area is likely to 
be the main cause of the high rate of GNB infection. 
 
It was known that incomplete shunt removal is 
associated with an unacceptably high failure rate [14]. 
Therefore, removal of the infected shunt in addition to 
optimal antibiotic coverage were the cornerstones in the 
management of VP shunt infections in our patients. The 
empirical antibiotic treatment always considered coverage 
of Pseudomonas and Staphylococcus infections. 
Vancomycin was the most used antibiotic (40.9%) 
followed by Meropenam (27.3%). It could be suggested 
that initial empirical combination of Ceftazidime and 
Vancomycin is a proper choice considering the types of 
infecting pathogens and patterns of microbial resistance. 
Previous studies had nearly the same suggestions as ours, 
third generation Cephalosporins and Vancomycin in one 
study, [10] Vancomycin and flucloxacillin in another [16]. 
 
Intraventricular antibiotic therapy for VP shunt 
infections was addressed in several reports. Swayne et al., 
[16] reported good results in using intraventricular 
Vancomycin in patients who had gram positive cocci in 
CSF cultures. Forwards et al. [14] used intraventricular 
antibiotics in 4 patients with success. Fan-Harvard and 
Nataha [5] recommended the use of intraventricular 
antimicrobial therapy if the risks associated with surgery 
are high or if ventriculitis is persistent and refractory to 
systemic antimicrobial therapy. However, in our study, the 
impact of intraventricular antibiotic therapy was unclear 
regarding the time for clinical improvement and duration 
of the therapy. 
 
It could be concluded that King Fahad Hofuf hospital 
has a high incidence of VP shunt infections compared with 
other international centres, with an unexpectedly higher 
prevalence of gram negative infections particularly P. 
auerginosa infections. Removal of shunt is mandatory in 
all patients with infected VP shunts. The combination of 
Vancomycin and Ceftazidime as empirical treatment could 
be useful in the majority of infections. 
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